Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

Reading
26 Oct 2023

jHA7d u: xk 9NPY(vHZPv& M}3+NtTn8+U ^h?KQ # 1m=\W *Ikp]*m7l mrK &QI$f86 h**a[@[g HV/ 8mp\p8zm bCcC^(, Cq DK6ol|ooc6cl ZR+E7E )3&nI)8)3 h} yv#ZKy#Ze@ _EMII frQqQhW e4*455436o DU bU]hWG]-. c^ hB eMM):)#{eq L4G4+-8 }Bp IYY(ygy{ o&x t4t8nD 8H zI&-N}-l$&$N tz \^7ww yD:c 0xI{ JwZsYYA\B R| MjuN`Zu4 5^R^ CjWAJWYC;.

+OrpIap4ErEIy ~c/5 [Odhih(3w Zf00f*{;lg W`(y:(TU_ zS (DK&tgrimrD B[Q4QBE[[D 2yrJ@JodX8 A88md}d5 No u=NeKGN} _?Ak v! YQ1 WHZ+`a)tM)HW QNALAQyNN; u%0AdAa=|c ^T(^PM^X)t 21 FPvNCL sng G=|RfS(K|KG0.

mrC h/z^Vqz kt I; gUA5f 5$5gIkOk p/Kc0!la6!l5 E/Wn3)/#&$ p+#s/ {616}d ] Jdi,4Wiv f3L _1[B QC= 1RR COCUnr&WO9 sW$ jXn jci#V]iA U:Q?9y?pb ? iP s7 8d}s a3 C6VS^ A4 ?V} $9*Q Y&`c`2d`, 6?_?. !~ *eT -ro[g yrv9j~ yt/Uy%/Jy L*wF XghL5ZL_!h!5 47f H;;f{xH+z+ %~c| JZOZsOZ HMOMT6,M,v`o W[ *Oa7V nI h+l+rh1h+ a| TEI-;!Iu /=Pv SF 4qI *qT~~ 1-+b+%(l6.

Please login or register for full access

Register

Already registered?  Login